润燥止痒胶囊在成人轻中度特应性皮炎治疗中的作用

目的探讨润燥止痒胶囊在成人轻中度特应性皮炎(Atopic Dermatitis,AD)治疗中的作用。方法将入选的AD患者随机分为治疗组32例,采用润燥止痒胶囊、凡士林乳膏和莫匹罗星软膏(百多邦)联合治疗;对照组21例,采用凡士林乳膏和莫匹罗星软膏治疗,均连续用药4周,采用SCORAD积分评价疗效。结果治疗组与对照组治疗前、后SCORAD积分均有所下降(P<0.01),治疗组的SCORAD积分下降明显大于对照组(P<0.05),治疗组的瘙痒积分明显下降(P<0.01),对照组的瘙痒积分无明显下降,治疗组有效率(62.50%)大于对照组(33.33%)。结论润燥止痒胶囊、凡士林乳膏和莫匹罗星软膏(百多邦)联合治疗成人轻中度AD可以改善病情,且润燥止痒胶囊可减轻瘙痒症状,并提高有效率。     

莫匹罗星软膏联合西替利嗪及氢化可的松软膏治疗湿疹疗效观察

目的观察莫匹罗星软膏联合西替利嗪及氢化可的松软膏与使用西替利嗪及氢化可的松软膏治疗湿疹的疗效。方法治疗组首先使用莫匹罗星软膏,3次/d,连用1周,然后使用氢化可的松软膏,2次/d,连用1周;对照组使用氢化可的松软膏,2次/d,连用2周。两组均使用抗组胺药西替利嗪止痒。结果治疗组58例中有56例可评价疗效,治愈率71.43%,有效率92.86%;对照组58例中有54例可评价疗效,治愈率53.70%,有效率74.07%。两组有效率比较差异有显著性(χ2=7.08,P<0.05)。结论莫匹罗星软膏联合西替利嗪及氢化可的松软膏治疗湿疹效果好,无明显不良反应。     

卤米松乳膏联合莫匹罗星软膏治疗湿疹疗效观察

目的观察卤米松乳膏联合莫匹罗星软膏与单独使用卤米松乳膏治疗湿疹的临床疗效。方法治疗组交替使用卤米松乳膏和莫匹罗星软膏,每天各2次,每次用药间隔时间超过2 h以上;对照组单独使用卤米松乳膏,2次/d。连续用药2周。结果治疗组共观察78例,治愈率78.21%,有效率97.44%;对照组78例,治愈率58.97%,有效率85.9%;两组有效率比较差异有显著性(χ2=6.80,P<0.05)。结论交替使用卤米松乳膏和莫匹罗星软膏治疗湿疹效果好,无明显不良反应。     

2%夫西地酸乳膏治疗细菌感染性皮肤病临床观察

目的评价2%夫西地酸乳膏治疗细菌感染性皮肤病的疗效和安全性。方法60例细菌感染性皮肤病患者,治疗组30例外擦2%夫西地酸乳膏,2～3次/d;对照组30例外擦2%莫匹罗星软膏,3次/d,疗程7天。结果治疗组有效率86.6%;对照组有效率90.0%,两组疗效差异无显著性(P>0.05)。治疗期间未出现不良反应。结论2%夫西地酸乳膏与莫匹罗星软膏对各种感染性皮肤病均有较好疗效,安全性高,患者依从性好。     

他克莫司软膏治疗系统性红斑狼疮面部皮损疗效观察

目的观察他克莫司软膏治疗系统性红斑狼疮面部皮损的疗效。方法将62例患者随机分为两组,治疗组予皮质类固醇激素+外用他克莫司软膏,对照组予皮质类固醇激素+外用丁酸氢化可的松乳膏。疗程均4周,比较治疗前后症状及体征的改善情况。结果治疗4周后两组患者的红斑、鳞屑、瘙痒等症状均有明显改善,两组疗效在治疗第1,2,4周后差异均无显著性(P均>0.05)。结果他克莫司软膏治疗系统性红斑狼疮面部皮损有较好的疗效。     

长效抗菌材料治疗新生儿皮疹的疗效观察

目的观察物理抗菌剂(洁悠神JUC)长效抗菌材料治疗新生儿皮疹的临床疗效,为临床治疗新生儿皮疹提供新的用药指导。将2 932例新生儿皮疹患儿随机分为观察组和对照组。观察组用JUC喷洒创面,对照组采用莫匹罗星涂抹,治疗3d、7d后评价疗效。结果观察组治疗3d、7d有效率为99.11%、100.00%,对照组治疗3d、7d有效率为19.47%、77.52%,两组总有效率比较差异有统计学意义(P0.05)。结论长效抗菌材料治疗新生儿皮疹疗效优于莫匹罗星,安全方便,缩短病程,近远期疗效无明显差异,值得推广应用。     

葛匹罗星软膏治疗耳环孔感染疗效分析

采用双盲法自身对照试验，应用莫匹罗星软膏及红霉素软膏治疗42例耳环孔感染，治疗3天及7天时病情积分均值莫匹罗星组分别为3.52±2.37，1.02±1.41，红霉素软膏组分别为5.88±2.61，2.93±2.68；总有效率莫匹罗星组与红霉素软膏组分别为97.62％，76.19％(P< 0.01)。细菌敏感试验及细菌清除率两组相比差异显著(P< 0.01)。莫匹罗星临床疗效及细菌清除作用强于红霉素软膏。     

龙珠软膏联合百多邦莫匹罗星软膏外用治疗蚂蚁螫伤的效果

目的探讨龙珠软膏联合百多邦莫匹罗星软膏外用治疗蚂蚁螫伤的效果。方法选取厦门市第五医院2020年2月—2021年1月收治的76例蚂蚁螫伤患者,根据随机数字表法分为观察组和对照组,各38例。观察组采用龙珠软膏联合百多邦莫匹罗星软膏治疗,对照组采用百多邦莫匹罗星软膏治疗,两组均治疗2个疗程,7 d为1个疗程。观察两组症状改善情况、临床疗效及治疗满意度。结果观察组红肿消退时间、疼痛消失时间、脓疱痊愈时间均短于对照组(P<0.05)。观察组临床总有效率高于对照组(P<0.05)。观察组治疗满意度高于对照组(P<0.05)。结论在蚂蚁螫伤的临床治疗中,龙珠软膏和百多邦莫匹罗星软膏均可作为外用药物的选择,两种药物联合应用可有效促进红肿、疼痛、脓疱等症状的快速消退,减轻患者的痛苦。     

金黄膏联合糖皮质激素治疗特应性皮炎临床疗效观察

目的评价金黄膏联合糖皮质激素治疗特应性皮炎的临床疗效。方法治疗组36例,外用金黄膏和丁酸氢化可的松软膏;对照组36例用莫匹罗星软膏和丁酸氢化可的松软膏,用法均为每日早晚各项1次涂搽患处。治疗第1,2,4周后观察疗效及评分。结果治疗1,2,4周后,治疗组的有效率分别为25.00%、47.22%和72.22%;对照组分别为36.11%、58.33%和80.55%,两组疗效比较差异无显著性意义(P>0.05)。结论金黄膏联合糖皮质激素外用治疗特应性皮炎有明显疗效。     

夫西地酸乳膏治疗化脓性皮肤病的临床疗效观察

目的评价夫西地酸治疗化脓性皮肤病的效果和安全性。方法对60例化脓性皮肤病采用夫西地酸乳膏局部外用治疗,并与60例莫匹罗星软膏组作对照,均3次/d,疗程7天。结果夫西地酸组与莫匹罗星组有效率分别为83.33%和85.00%,细菌清除率分别为87.1%和88.89%,差异均无显著性(P>0.05)。结论夫西地酸乳膏和莫匹罗星软膏治疗化脓性皮肤病的疗效相当,不良反应发生率低。     

长期外用他克莫司软膏对特应性皮炎患者免疫力的影响

目的:探讨特应性皮炎患者长期外用他克莫司软膏治疗后血药浓度的变化以及对外周血淋巴细胞亚群的影响。方法:使用他克莫司软膏(0.1%)治疗12例特应性皮炎患者,疗程12个月,于治疗前和治疗结束后使用流式细胞术检测外周血中淋巴细胞亚群,治疗一周时和治疗结束后使用ELISA检测患者他克莫司血药浓度,比较治疗前后的变化。结果:淋巴细胞亚群的变化在治疗前后比较,差异均无统计学意义(P值均>0.05);治疗1周时,他克莫司血药浓度为(1.73±0.48)ng/mL,治疗12个月后浓度为(1.07±0.42)ng/mL,两者差异具有统计学意义(t=16.85,P<0.05);他克莫司软膏使用总量与Th/Ts比值变化量无相关性(r=-0.40,P>0.05)。结论:特应性皮炎长期外用他克莫司软膏存在低水平的系统吸收,他克莫司低水平系统暴露对特应性皮炎患者的外周血淋巴细胞亚群无影响。     

Efficacy of pimecrolimus 1% cream in the long term management of atopic hand dermatitis. A double-blind RCT

Background: Efficacy and steroid sparing effects of pimecrolimus 1 % cream in atopic dermatitis have been shown recently, but there is no data on efficacy in long term management of atopic hand dermatitis. This study aims to investigate the efficacy of pimecrolimus 1 % cream as maintenance therapy in patients suffering from atopic hand dermatitis. Patients and Methods: A double‐blind vehicle controlled study in 40 adult patients with atopic hand dermatitis (IGA < 3) comparing the efficacy of twice daily application of pimecrolimus 1 % cream given as maintenance treatment versus vehicle over a 8 week period after clinical response (IGA < 2) to a 1–3 week pre‐treatment with mometasone fuorate 0.1 % was performed. Primary endpoint was the time to relapse (IGA > 3). Results: Thirty‐six out of 40 patients were randomised to receive either pimecrolimus 1 % (P) or vehicle cream (V). The number of patients with stable remission in patients randomised to pimecrolimus (53.8 %) and vehicle (43.8 %) did not achieve statistical significance between the groups (p = 0.41). Subgroup analysis of patients with initially moderate dermatitis (IGA = 3, n = 20) showed a trend towards a better outcome for the pimecrolimus group (stable remission P = 81.8 % versus V = 55.6 %) (p = 0.244). Conclusions: Pimecrolimus 1 % cream twice daily was not superior to vehicle in the sequential maintenance therapy of atopic hand dermatitis, but efficacy in moderate forms should be investigated in further studies.     

他克莫司软膏治疗成人特应性皮炎

目的研究他克莫司软膏治疗成人特应性皮炎(AD)的疗效与安全性.方法采用随机、双盲、赋形剂对照临床研究方法,将44例成人AD患者随机分为3组,按111比例分别接受0.1%(0.1%组)、0.03%(0.03%组)他克莫司软膏和赋形剂(赋形剂组)治疗.观察治疗第1、2和3周的临床疗效和不良反应.结果他克莫司软膏0.1%组和0.03%组的有效率分别为86.7%(13/15)和78.6%(11/14),均明显高于赋形剂组(42.9%,6/14),差异非常显著(P＜0.001).总体疗效比较0.1%组优于0.03%组,差异显著(P=0.043).治疗后第1、2、3周0.1%组和0.03%组的主要症状-体征指标平均值均明显低于赋形剂组,组间差异显著(P＜0.05～P＜0.001).治疗后患者的生活质量明显改善.药物相关不良反应主要为一过性局部刺激,但组间比较无统计学意义(P＞0.05),3组均未出现严重不良反应.结论他克莫司软膏治疗成人特应性皮炎安全有效.     

Efficacy and safety of topical OPA‐15406, a new phosphodiesterase 4 inhibitor,in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized,double‐blind,placebo‐controlled study

The efficacy and safety of topical OPA‐15406, a new phosphodiesterase 4 inhibitor, were examined in Japanese patients aged 15–70 years with atopic dermatitis in a phase 2, randomized, double‐blind, vehicle‐controlled study. Two hundred patients were randomized to three treatment groups at a 1:1:1 ratio to receive OPA‐15406 0.3%, OPA‐15406 1% or vehicle ointment twice daily for 8 weeks. The OPA‐15406 1% group was superior to the vehicle group in terms of the incidence of success based on the Investigator Global Assessment score at week 4 (P = 0.0328), which was the primary end‐point, while the OPA‐15406 0.3% group showed a trend toward improvement in the primary end‐point. The mean Eczema Area and Severity Index total score and subscale (erythema, induration/papulation, excoriation and lichenification) scores, the Visual Analog Scale pruritus score and the Patient‐Oriented Eczema Measure score were significantly improved and the percentage of affected body surface area was significantly decreased in both OPA‐15406 groups relative to the vehicle group as early as week 1, and the improved scores and decreased percentages were generally maintained until week 8. No deaths or serious treatment‐emergent adverse events occurred in the OPA‐15406 treatment groups. Treatment‐emergent adverse events frequently observed across treatment groups were worsening of atopic dermatitis, viral upper respiratory tract infection and pruritus, all of which were mild or moderate in severity in the OPA‐15406 groups. OPA‐15406 1% ointment showed favorable efficacy and safety profiles, indicating a promising treatment option for patients with atopic dermatitis.     

Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized,vehicle‐controlled exploratory trial

This exploratory study was designed to evaluate the safety and efficacy profile of the topical phosphodiesterase 4 inhibitor E6005 in Japanese children with mild‐to‐moderate atopic dermatitis. The present randomized, multicenter study included 62 patients who were treated with 0.05% E6005, 0.2% E6005 or vehicle ointment twice daily for 2 weeks. Safety and pharmacokinetics were assessed with a focus on the occurrence of adverse events and the whole blood concentrations of E6005 and its metabolite. Exploratory efficacy evaluations included assessments of lesion severity and pruritus score. The 2‐week application of topical E6005 was safe and well tolerated with no cutaneous adverse events. The whole blood concentration of E6005 was quantified in only one subject receiving 0.2% E6005 treatment, while its major metabolite was undetectable. The 0.2% E6005 group showed a greater decrease in the severity score than the vehicle group (?45.94% vs ?32.26%), although this difference was not statistically significant. Similarly, the treatment success rate according to the investigator's global assessment of the total application sites was higher in the 0.2% E6005 group than in the vehicle group (34.4% vs 20.0%). Moreover, the 0.2% E6005 group showed a greater decrease in the pruritus score than the vehicle group (?37.5% vs ?6.7%) in a predefined subpopulation. The efficacy of 0.05% E6005 treatment was comparable to that of vehicle treatment. These results suggest that topical 0.2% E6005 treatment is safe and effective in children with atopic dermatitis, although further large confirmatory clinical trials are warranted.     

Spotlight on topical pimecrolimus in atopic dermatitis

Pimecrolimus (SDZ ASM 981), an ascomycin derivative, is a nonsteroid, has anti-inflammatory activity, and has demonstrated efficacy in reducing symptoms of atopic dermatitis in adult and pediatric patients when applied topically. Compared with vehicle, topical pimecrolimus 1.0% cream was significantly more effective at reducing symptoms of atopic dermatitis, as measured by the Eczema Area and Severity Index (EASI), in infants aged 3 to 23 months, children aged 2 to 17 years, and adults. The median reductions from baseline in the total EASI score in adults after treatment with pimecrolimus 1.0% or corresponding vehicle twice daily for 3 weeks were 47 and 0%, respectively. In infants and children, treatment with pimecrolimus 1.0% twice daily for 6 weeks resulted in significant decreases in mean EASI scores compared with vehicle. The severity of pruritus was significantly reduced in patients of all age groups after topical treatment with pimecrolimus 1.0% cream. Compared with vehicle, the incidence of eczematous flares was also reduced by intermittent long-term use of topical pimecrolimus 1.0% in adults, children and infants. Sixty-one percent of children treated with pimecrolimus for 1 year completed the first 6 months of treatment without experiencing a flare, compared with 35% of patients who received vehicle. Furthermore, the use of topical corticosteroids for the treatment of uncontrolled flares in adults, children and infants was lower in the pimecrolimus groups than in the vehicle groups. Topical pimecrolimus 1.0% cream is well tolerated in atopic dermatitis patients of all age groups. There were no clinically relevant systemic adverse events reported from any of the studies in patients with atopic dermatitis. The most frequently reported adverse events pertained to application site reactions, such as burning and a feeling of warmth. In conclusion, topical pimecrolimus 1.0% cream has shown efficacy in the treatment of mild to moderate atopic dermatitis in infants, children and adults. Although tolerability data concerning infants and children have not yet been published in full, the drug appears to be well tolerated in all age groups, and there have been no reports of clinically relevant systemic adverse events. Furthermore, pimecrolimus has shown no potential for skin atrophy, a problem commonly associated with treatment with topical corticosteroids. Topical pimecrolimus 1.0% provides a promising and well tolerated treatment option in the management of infants, children and adults with mild to moderate atopic dermatitis.     

湿包裹治疗儿童重度特应性皮炎的疗效观察

目的 观察湿包裹(WWT)治疗儿童重度特应性皮炎(AD)的疗效和安全性.方法 2018年9月-2019年9月在南京儿童医院皮肤科门诊诊断为重度AD的患儿(符合Williams诊断标准,SCORAD ＞50分)40例,随机分为WWT组(n =20)和传统治疗组(n=20).WWT组采用0.1％糠酸莫米松乳膏联合2％莫匹罗...     

他克莫司软膏治疗儿童特应性皮炎的临床研究

目的　评价他克莫司软膏治疗儿童特应性皮炎 (AD)的疗效与安全性。方法　采用随机、双盲、赋形剂对照临床研究方法,将 36例儿童AD患者随机分为两组,按 1∶1比例分别接受 0. 03%他克莫司软膏或赋形剂治疗,观察治疗第 1, 2和 3周的临床疗效和不良反应。结果　0. 03%他克莫司软膏组有效率为 83. 3% (15 /18),明显高于赋形剂组的 27. 8% (5 /18),差异非常显著(P<0. 001);总体疗效比较,他克莫司软膏组亦优于赋形剂组 (P=0. 002);治疗后第 1,2, 3周患者的主要症状 /体征指标平均值均明显低于赋形剂组,组间差异显著(P<0.01~P<0. 05),治疗后患者的生活质量亦明显改善。药物相关不良反应主要表现为一过性局部刺激,组间比较差异无显著性 (P>0. 05)。两组患者均未出现严重不良反应。结论　0. 03%他克莫司软膏治疗儿童特应性皮炎安全有效。     

0.05%地奈德乳剂治疗内源性湿疹的临床研究

目的　评价 0 .0 5 %地奈德乳剂治疗内源性湿疹包括特应性皮炎 3周的疗效和安全性。方法　入组包括特应性皮炎在内的内源性湿疹 84例 ,采用随机、双盲、基质对照、平行组对比研究 ,受试者外涂药物于受累区域 ,2次 /d ,连续治疗 3周。结果　试验组靶皮损总积分 (TSS)由治疗前 8.3 1± 1.85降至 1.19± 1.69,TSS改善 84.99% ;对照组TSS由 8.43± 1.67降至 3 .10± 2 .2 4,TSS改善 63 .5 4%。试验组与对照组靶皮损各项观察指标均得到改善 ,但试验组的改善优于对照组。总体改善评价试验组总有效率为 80 .95 % ,对照组为 5 2 .3 8% ,两组比较差异有显著性 (P <0 .0 5 )。　结论　 0 .0 5 %地奈德乳剂治疗内源性湿疹的临床治愈率、总体疗效优于基质 ,且不良反应发生率低 ,是一种安全有效的外用皮质类固醇激素。     

Staphylococcal colonization in atopic dermatitis and the effect of topical mupirocin therapy

Forty-nine patients with atopic dermatitis entered a double blind lacebo controlled cross-over study of mupirocin, a new topical antistaphylococcal antibiotic. Forty-five patients were evaluable. Quantitative bacteriological assessment before treatment showed that heavy colonization of the skin with Staphylococcus aureus was present in nearly all patients even in the absence of overt infection. However, the bacterial count was significantly reduced by 2 weeks' treatment with topical mupirocin, but not by the placebo. Moreover, a significant reduction of clinical severity was also observed after treatment with mupirocin, which was maintained over the following 4 weeks, although recolonization occurred during this period, with bacterial counts rising to pre-treatment levels. Despite recolonization, clinical deterioration was not observed during the trial period. No serious side-effects were observed. Phage typing showed that 50% of patients carried more than one bacterial phage type. Recolonization in eight patients (17%) was with a ‘new’ strain that had not previously been isolated.